BioNexus Gene Lab Corp
BioNexus Gene Lab Corp
No insider data available
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
Cash | - | - | - | - | - | - | - | - | - | 2 | 3 | 5 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Cash Equivalents At Carrying Value | - | - | - | - | - | 1 | 2 | 2 | 2 | - | 3 | - | |||||
Deposits Assets | - | - | - | - | - | 3 | 3 | 2 | 3 | 3 | 3 | 1 | |||||
Cash And Cash Equivalents At Carrying Value | 2 | 1 | 2 | 1 | 2 | - | 2 | - | - | - | - | - | |||||
Deposits Assets Current | 2 | 3 | 2 | 2 | 2 | - | 3 | - | - | - | - | - | |||||
Assets Current | |||||||||||||||||
Accounts Receivable Net | - | - | 1 | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Assets Current | 5 | 5 | 5 | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 8 | 8 | |||||
Accounts Receivable Net Current | 0 | 0 | 1 | 2 | 2 | - | 1 | - | - | - | - | - | |||||
Other Receivables Net Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Assets Noncurrent | |||||||||||||||||
Assets Noncurrent | 4 | 4 | 4 | 2 | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 3 | |||||
Other Assets Current | 1 | 0 | 0 | - | - | - | 0 | - | - | - | - | - | |||||
Income Taxes Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Inventory Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Finance Lease Right Of Use Asset | - | 0 | - | - | - | - | - | - | - | - | - | - | |||||
Property Plant And Equipment Net | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | |||||
Other Investments | - | - | - | - | - | - | - | 2 | 2 | 2 | 2 | 2 | |||||
Equity Securities Fv Ni Current And Noncurrent | - | - | - | - | - | 1 | 1 | - | - | - | 2 | - | |||||
Equity Method Investments | 2 | 2 | 2 | 0 | 1 | - | 1 | - | - | - | - | - | |||||
Assets | 9 | 9 | 9 | 8 | 9 | 9 | 10 | 11 | 11 | 11 | 11 | 11 | |||||
Accounts Payable Current | - | - | - | - | - | 1 | 2 | 1 | 1 | 1 | 1 | 2 | |||||
Accounts Payable Trade Current | 0 | 0 | 0 | 0 | 1 | - | 2 | - | - | - | - | - | |||||
Other Accounts Payable And Accrued Liabilities | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Liabilities Current | |||||||||||||||||
Liabilities Current | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 2 | |||||
Finance Lease Liability Current | - | 0 | - | - | - | - | - | - | - | - | - | - | |||||
Customer Advances Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | |||||
Taxes Payable Current | - | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Liabilities Noncurrent | |||||||||||||||||
Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Deferred Income Tax Liabilities Net | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Finance Lease Liability Noncurrent | - | 0 | - | - | - | - | - | - | - | - | - | - | |||||
Liabilities | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |||||
Common Stock Value | 20 | 20 | 20 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | |||||
Additional Paid In Capital | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | |||||
Stockholders Equity | |||||||||||||||||
Stockholders Equity | 8 | 8 | 9 | 7 | 8 | 8 | 8 | 9 | 10 | 9 | 10 | 9 | |||||
Retained Earnings Accumulated Deficit | -7 | -7 | -6 | -5 | -5 | -4 | -3 | -3 | -2 | -2 | -2 | -2 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | -0 | -0 | -0 | -0 | -0 | -0 | -1 | -0 | -1 | -1 | -1 | -1 | |||||
Liabilities And Stockholders Equity | 9 | 9 | 9 | 8 | 9 | 9 | 10 | 11 | 11 | 11 | 11 | 11 | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | |||||
Shares Outstanding | 2 | 2 | 2 | 2 | 2 | 18 | 2 | 18 | 18 | 18 | 18 | 18 | |||||
Preferred Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Authorized | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Deposit Assets | 1 | 2 | 2 | 2 | 2 | 2 | 1 | - | - | - | 1 | - | |||||
Allowance For Doubtful Accounts Receivable Current | 1 | 1 | 1 | 1 | 0 | 1 | 1 | - | - | - | 1 | - | |||||
Other Inventory In Transit | - | - | 0 | 0 | 0 | - | 0 | - | - | - | 0 | - | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 8.96% | 0.54% | -34.62% | - | - | - | - | - | - | - | - | - |
| 2025 | 1.97% | 111.51% | 112.83% | 2.07% | -2.44% | -4.32% | -9.27% | -13.02% | -42.67% | -5.07% | 1.38% | -6.45% |
| 2024 | -4.14% | -20.00% | -17.59% | -7.24% | -4.52% | -14.71% | -3.00% | 53.67% | 36.00% | 0.75% | 16.98% | 142.64% |
| 2023 | - | - | - | 58.33% | -2.22% | -43.19% | -14.04% | -17.77% | -36.68% | -7.94% | -11.75% | -26.35% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Metrics | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Metric history beyond 3 years is for subscribers only. Unlock 17+ years of history across 90+ calculated metrics Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | 6.08 | 6.52 | 10.46 | 8.30 | 3.63 | 4.19 | 3.81 | 4.98 | 5.60 | 4.61 | 4.93 | 5.03 | |||||
| Quick Ratio | 5.28 | 5.69 | 9.16 | 6.81 | 2.94 | 3.44 | 3.10 | 3.99 | 4.87 | 3.98 | 4.24 | 4.36 | |||||
| Working Capital | 4.13M | 4.40M | 4.93M | 4.95M | 4.62M | 4.98M | 5.48M | 5.62M | 6.44M | 6.19M | 6.42M | 6.63M | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | 0.12 | 0.12 | 0.07 | 0.12 | 0.25 | 0.22 | 0.25 | 0.17 | 0.17 | 0.19 | 0.18 | 0.19 | |||||
| Interest Coverage TTM | - | - | - | - | -481.76 | -263.25 | -146.55 | -70.18 | -192.03 | -228.28 | -231.16 | -325.49 | |||||
| Debt Ratio | 0.11 | 0.10 | 0.07 | 0.11 | 0.20 | 0.18 | 0.20 | 0.15 | 0.14 | 0.16 | 0.15 | 0.16 | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 0.34 | 0.57 | 0.75 | 1.02 | 0.93 | 0.90 | 0.87 | 0.82 | 0.96 | 1.01 | 0.97 | 1.07 | |||||
| Days Sales Outstanding TTM | 109.01 | 5.49 | 46.27 | 58.70 | 70.77 | - | 52.83 | - | - | - | - | - | |||||
| Receivables Turnover TTM | 3.35 | 66.50 | 7.89 | 6.22 | 5.16 | - | 6.91 | - | - | - | - | - | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | -1.07 | -1.20 | - | -1.28 | -1.63 | -1.18 | -0.09 | -0.52 | -1.25 | -0.15 | -0.17 | - | |||||
| Free Cash Flow Per Share TTM | -0.64 | -0.49 | -0.78 | -0.99 | -1.31 | -0.17 | -1.29 | -0.18 | -0.14 | -0.11 | -0.11 | -0.04 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Margin Metrics | |||||||||||||||||
| Gross Profit Margin TTM | 12.34% | 13.95% | 14.62% | 14.77% | 14.11% | 13.68% | 13.56% | 13.47% | 13.88% | 13.56% | 13.61% | 13.56% | |||||
| Operating Profit Margin TTM | -81.82% | -54.36% | -39.93% | -24.81% | -31.24% | -22.81% | -16.55% | -9.72% | -22.77% | -26.82% | -26.54% | -28.77% | |||||
| Net Profit Margin TTM | -82.36% | -54.70% | -40.20% | -24.27% | -30.71% | -22.86% | -16.81% | -10.17% | -24.02% | -27.25% | -26.91% | -29.94% | |||||
Growth Metrics | |||||||||||||||||
| Net Revenue Growth (1Y) | -67.27% | -42.69% | -21.93% | 2.22% | 4.01% | -5.21% | -2.66% | -10.42% | -11.35% | -4.88% | -10.60% | -8.80% | |||||
| Net Income Growth (1Y) | -12.21% | 37.16% | 86.73% | 143.94% | 33.00% | -20.49% | -39.20% | -69.57% | 291.94% | 502.52% | 638.57% | 2,719.46% | |||||
| EPS Growth (1Y) | -34.75% | 919.47% | 38.80% | 2,339.60% | 1,207.93% | -21.82% | 497.81% | -69.87% | 3,753.74% | 5,824.32% | 505.17% | 27,427.76% | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | -1.83 | -1.78 | -3.20 | -4.28 | -1.88 | -20.02 | -3.15 | -84.92 | -38.05 | -46.83 | -35.62 | -50.02 | |||||
| P/B TTM | 0.61 | 0.64 | 1.11 | 1.44 | 0.73 | 5.46 | 0.60 | 8.52 | 8.79 | 13.35 | 9.70 | 16.62 | |||||
| P/S TTM | 1.51 | 0.97 | 1.29 | 1.04 | 0.58 | 4.58 | 0.53 | 8.63 | 9.14 | 12.76 | 9.58 | 14.97 | |||||
| Market Cap | 4.71M | 5.18M | 9.55M | 9.83M | 5.52M | 42.40M | 5.03M | 79.96M | 83.92M | 124.73M | 93.64M | 154.80M | |||||
| Enterprise Value | 2.32M | 3.89M | 7.17M | 8.67M | 3.98M | 40.31M | 3.45M | 75.82M | 78.51M | 120.30M | 89.12M | 148.65M | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | -1.54M | -1.19M | -1.88M | -1.79M | -2.35M | -3.09M | -2.32M | -3.32M | -2.55M | -1.91M | -1.97M | -748.55K | |||||
| Net Debt | -2.39M | -1.28M | -2.38M | -1.15M | -1.54M | -2.09M | -1.58M | -4.14M | -5.41M | -4.44M | -4.52M | -6.15M | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
| NCAV | |||||||||||||||||
| NCAV Per Share TTM | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
BioNexus Gene Lab Corp (BGLC) — SEC Financial Statements & Analysis
BioNexus Gene Lab Corp (BGLC) is a services-medical laboratories company, incorporated in WY. BioNexus Gene Lab Corp trades on Nasdaq as: BGLC. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), BioNexus Gene Lab Corp reported a -67.27% year-over-year revenue growth, a Gross Profit Margin of 12.34% (TTM), a Debt-to-Equity ratio of 0.12x, a Price-to-Sales (P/S) ratio of 1.51x (TTM), a Price-to-Book (P/B) ratio of 0.61x (TTM), at a market cap of $4.71M. Figures below are sourced from SEC EDGAR, as-filed.
- Net Revenue TTM Growth 1Y
- -67.27%
- Gross Profit Margin TTM
- 12.34%
- Debt To Equity
- 0.12x
- P/S TTM
- 1.51x
- P/B TTM
- 0.61x
- Market Cap
- $4.71M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is BioNexus Gene Lab Corp in?
BioNexus Gene Lab Corp (BGLC) operates in the Services-Medical Laboratories industry.
What is BGLC's market cap?
BioNexus Gene Lab Corp (BGLC) has a market capitalization of $4.71M as of 2026-06-30.
What exchange does BGLC trade on?
BioNexus Gene Lab Corp (BGLC) trades on the Nasdaq.
Where is BioNexus Gene Lab Corp incorporated?
BioNexus Gene Lab Corp is incorporated in WY.